



Diagonal Bio announces change of news platform

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that, effective Monday, 28 April 2025, the Company will transition its news distribution service from Cision News to Modular Finance (MFN).

Starting from Monday 28 of April, those wishing to subscribe to Diagonal Bio's news updates can register on the Company's website. Please note that the system does not allow for subscribers to be transferred from Cision to MFN automatically. All current subscribers are kindly requested to re-subscribe on the Company's website.

For additional information about Diagonal Bio, please contact:

Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.